The study showed elevated non-HDL-c was associated with conglomeration of multiple risk factors for ASCVD. The result is predictable and not novel. It has been shown in many previous publications. However, one major concern about the methodology: Were the blood pressure and sugar measured before any treatment or just on treatment? The authors should clarify it, because it may change the risk calculation in some patients, esp. for those already with hypertension or diabetes mellitus from the beginning of the study. 